We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Our Scientific Affairs Group confirmed that this compound has shown some encouraging signs in Phase 2 trials and has the potential to improve the standard of care for patients with ovarian cancer that recurs after initial treatment.